SCHEMBL14624360

SCHEMBL14624360

CC(C)N1CC2(CCN(C(=O)OCc3ccccc3)CC2)c2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.59
HDAC6 Q9UBN7 3/20 0.59
HDAC8 Q9BY41 2/20 0.59
P2RY1 P47900 1/20 0.52
XIAP P98170 1/20 0.50
BIRC2 Q13490 1/20 0.50
FFAR1 O14842 1/20 0.50
TACR1 P25103 5/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1L1 Q9UHC9 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM1A O60341 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC2 Q92769 1/20 0.46
CYP2C19 P33261 1/20 0.45
TACR2 P21452 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14623151 0.89 APP (0.47) HDAC1HDAC6HDAC8FFAR1NPC1L1
SCHEMBL1195680 0.86 HDAC1 (0.63) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL1195682 0.86 HDAC1 (0.63) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL14529872 0.84 HDAC1 (0.56) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL13228096 0.83 HDAC1 (0.68) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL12049087 0.83 HDAC1 (0.59) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL14530334 0.83 HDAC1 (0.61) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL14530335 0.83 HDAC1 (0.59) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL1587816 0.82 HDAC1 (0.61) HDAC1HDAC6HDAC8P2RY1XIAP
SCHEMBL2878354 0.82 TACR1 (0.68) HDAC1HDAC6HDAC8TACR1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007002637-A1 N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed